These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32790958)

  • 1. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
    Millar BC; McCaughan J; Rendall JC; Moore JE
    Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant
    Craddock VD; Steere EL; Harman H; Britt NS
    Antibiotics (Basel); 2023 Jun; 12(6):. PubMed ID: 37370396
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kong Y; Li C; Li G; Yang T; Draz MS; Xie X; Zhang J; Ruan Z
    Microbiol Spectr; 2022 Jun; 10(3):e0009922. PubMed ID: 35532225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility to delafloxacin of Pseudomonas aeruginosa with resistance to other quinolones (ciprofloxacin and levofloxacin).
    Jordán-Chaves JDD; Lobato-Cano R; Casas-Ciria J; Freyre-Carillo C; Santotoribio JD; de-la-Rubia-Martin MF
    Clin Microbiol Infect; 2024 Mar; 30(3):405-406. PubMed ID: 38103637
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis.
    Ribeiro ÁCDS; Santos FF; Valiatti TB; Lenzi MH; Santos INM; Neves RFB; Moses IB; Meneses JP; Di Sessa RGG; Salles MJ; Gales AC
    Braz J Infect Dis; 2024 Sep; 28(6):103867. PubMed ID: 39305936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of delafloxacin against bacterial isolates from osteoarticular and skin infections in Buenos Aires, Argentina].
    Nicola F; Azula N; Santoni G; Smayevsky J
    Rev Argent Microbiol; 2022; 54(2):114-119. PubMed ID: 34053809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.
    Dostal RE; Seale JP; Yan BJ
    Med J Aust; 1992 Jan; 156(1):20-4. PubMed ID: 1734188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.
    Zamorano L; Juan C; Fernández-Olmos A; Ge Y; Cantón R; Oliver A
    Clin Microbiol Infect; 2010 Sep; 16(9):1482-7. PubMed ID: 20002107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
    Law JP; Wood AJ; Friman VP
    Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
    Millar BC; Malnarcic CM; McCaughan J; Moore JE
    Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
    [No Abstract]   [Full Text] [Related]  

  • 16. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM; Hamilton VE; Thomas MR
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
    Saravolatz LD; Pawlak JM; Wegner C
    J Antimicrob Chemother; 2020 Sep; 75(9):2605-2608. PubMed ID: 32542310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.